OncoMatch/Clinical Trials/NCT06515314
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
Is NCT06515314 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AFP Specific T Cell Receptor T Cells for hepatic cell carcinoma.
Treatment: AFP Specific T Cell Receptor T Cells — This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Leukocytes≥3.0 x 10^9/L; blood platelets ≥75 x 10^9/L; hemoglobin≥85g/L; Absolute lymphocyte count≥0.8 x 10^9/L
Kidney function
Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN
Liver function
total bilirubin≤3×ULN; ALT/AST≤3×ULN
Cardiac function
LVEF≥50%
Leukocytes≥3.0 x 10^9/L; blood platelets ≥75 x 10^9/L; hemoglobin≥85g/L; Absolute lymphocyte count≥0.8 x 10^9/L Serum albumin ≥ 30g/L; total bilirubin≤3×ULN; ALT/AST≤3×ULN ; Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN; INR≤1.5×ULN; APTT≤1.5×ULN; LVEF≥50%; SpO2≥92%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify